Allen Lutz
BofA Securities, Research Division

[Audio Gap] Allen Lutz, health care tech and distribution analyst here at Bank of America. We are delighted to have McKesson here. We have Britt Vitalone, Executive Vice President and CFO. Thank you, Britt, for joining us.

Allen Lutz
BofA Securities, Research Division

Kicking off with the North American pharma business, we've gotten a lot of questions just around what, if anything, has changed as we went from 2025 to 2026. As we think about utilization, drug price changes. As you think about going from 2025 into 2026 in that North American pharma business, has anything changed? Is there a deceleration at all going on within that business as we think about gross profit dollar growth? And we'll start there.

Britt Vitalone
Executive VP & CFO

Yes. Well, first of all, thanks for having us here today. And maybe I'll just step back and say we're really pleased with how we finished our fiscal '26. We had a very strong fourth quarter in terms of revenue growth, adjusted operating profit growth and adjusted EPS. We had 3 of our 4 segments have double-digit adjusted operating profit growth. And for the full year, not only do we have strong revenue growth, but we had 15% AOP growth and 18% EPS growth, all above the long-range targets that we set. So there's a lot of really good momentum in the business.

As we think about our North American pharmaceutical distribution business, we continue to see stable and growing utilization. That's really one of the foundational building blocks for our